Strategy

Small molecules or biologics: that's the question

Interviewee/Contributer: Jean-Claude Muller

Organisation: Innovation and International Relationship

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Are botanical drugs a new model for pharma?

Interviewee/Contributer: Christian Hogg

Organisation: Hutchison China MediTech

Full text available to subscribers only. Click here for information on subscribing to MedNous.

A start-up genomics company explains why open-source software is important

Interviewee/Contributer: Richard Holland

Organisation: Eagle Genomics Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Time to engage with stem-cell therapy

Interviewee/Contributer: Alain Vertès

Organisation: London Business School

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Interview: 4-Antibody AG - How do you structure a biotech for divestment?

Interviewee/Contributer: Robert Burns

Organisation: 4-Antibody AG

Full text available to subscribers only. Click here for information on subscribing to MedNous.

A Big Pharma deal that shares risk and reward

Interviewee/Contributer: Bahija Jallal

Organisation: MedImmune

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Focus on ophthalmology: new treatment modality

Interviewee/Contributer: Patrik De Haes

Organisation: ThromboGenics NV

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Due diligence is more than a numbers game

Interviewee/Contributer: Anthony Sedgwick

Organisation: Silence Therapeutics Plc

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Kymab unlocks the power of the mouse

Interviewee/Contributer: Andrew Sandham

Organisation: Kymab Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

The role of technology providers in biotech

Interviewee/Contributer: John Burt

Organisation: PolyTherics Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content